Residents should consider the evidence behind alternative therapies used to control costs in such settings, e.g., use of streptokinase vs. recombinant tissue plasminogen activator (tPA) for thrombolysis in acute coronary syndrome and stroke. The gene discussed is PLAT; the disease is acute coronary syndrome.